Clinical significance of α‑ and β‑Klotho in urothelial carcinoma of the bladder

Hori,Shunta; Miyake,Makito; Onishi,Sayuri; Tatsumi,Yoshihiro; Morizawa,Yosuke; Nakai,Yasushi; Anai,Satoshi; Tanaka,Nobumichi; Fujimoto,Kiyohide

doi:10.3892/or.2016.5053

Clinical significance of α‑ and β‑Klotho in urothelial carcinoma of the bladder

Authors:
- Shunta Hori
- Makito Miyake
- Sayuri Onishi
- Yoshihiro Tatsumi
- Yosuke Morizawa
- Yasushi Nakai
- Satoshi Anai
- Nobumichi Tanaka
- Kiyohide Fujimoto
View Affiliations

Affiliations: Department of Urology, Nara Medical University, Kashihara, Nara 634‑8522, Japan
Published online on: August 25, 2016 https://doi.org/10.3892/or.2016.5053
Pages: 2117-2125

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non-muscle invasive bladder cancer (NMIBC) accounts for ~70% of all bladder cancers. One of the serious clinical issues related to the management of NMIBC is that it has significant potential to progress to muscle invasive bladder cancer (MIBC) after initial treatments. α‑Klotho (KLα), originally identified as an anti‑aging gene, has recently been reported to have antitumor effects in various malignancies. In contrast, β‑Klotho (KLβ) has been reported to have protumoral functions. However, the associations between KLα/KLβ and the biological behavior of urothelial carcinoma remain unclear. In the present study, we evaluated the association between clinicopathological background factors of NMIBC and the expression levels of KLα or KLβ. A high expression level of KLβ, but not KLα, was an independent predictive factor of short progression‑free survival for NMIBC. An elevated level of KLβ correlated with a higher incidence of lymphovascular invasion (LVI). We added in vitro assays using human bladder cancer cell lines to investigate the role of KLβ. Treatment with exogenous KLβ protein increased the proliferation, migration, transendothelial migration abilities and anchorage‑independent growth of the cell lines. In addition, the KLβ concentration in voided urine samples obtained before initial transurethral surgery was quantitated with enzyme‑linked immunosorbent assay (ELISA). The urine KLβ concentration was found to be higher in patients with bladder cancer than that in healthy volunteers. Our results suggest that KLβ plays important roles in tumor invasion and progression, and its concentration may be a valuable urine‑based marker for the detection of bladder cancer.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Miyake M, Fujimoto K, Anai S, Ohnishi S, Nakai Y, Inoue T, Matsumura Y, Tomioka A, Ikeda T, Tanaka N, et al: Clinical significance of heme oxygenase-1 expression in non-muscle-invasive bladder cancer. Urol Int. 85:355–363. 2010. View Article : Google Scholar : PubMed/NCBI
3	Nepple KG and O'Donnell MA: The optimal management of T1 high-grade bladder cancer. Can Urol Assoc J. 3(Suppl 4): S188–S192. 2009.PubMed/NCBI
4	Hendricksen K and Witjes JA: Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer. Curr Opin Urol. 17:352–357. 2007. View Article : Google Scholar : PubMed/NCBI
5	Kikuchi E, Fujimoto H, Mizutani Y, Okajima E, Koga H, Hinotsu S, Shinohara N, Oya M and Miki T; Cancer Registration Committee of the Japanese Urological Association: Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in japan: 1999–2001 report from the Japanese Urological Association. Int J Urol. 16:279–286. 2009. View Article : Google Scholar : PubMed/NCBI
6	Peyromaure M, Guerin F, Amsellem-Ouazana D, Saighi D, Debre B and Zerbib M: Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: Recurrence, progression and survival in a study of 57 patients. J Urol. 169:2110–2112. 2003. View Article : Google Scholar : PubMed/NCBI
7	Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L and Studer UE: A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: Recurrence, progression and survival. J Urol. 169:96–100; discussion 100. 2003. View Article : Google Scholar
8	Shelley MD, Jones G, Cleves A, Wilt TJ, Mason MD and Kynaston HG: Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): A systematic review. BJU Int. 109:496–505. 2012. View Article : Google Scholar : PubMed/NCBI
9	Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, Kirkels WJ, Silva FC, Oosterlinck W, Prescott S, et al: EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1–3 years of maintenance Bacillus Calmette-Guérin. Eur Urol. 69:60–69. 2016. View Article : Google Scholar
10	Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, et al: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 390:45–51. 1997. View Article : Google Scholar : PubMed/NCBI
11	Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, McGuinness OP, Chikuda H, Yamaguchi M, Kawaguchi H, et al: Suppression of aging in mice by the hormone Klotho. Science. 309:1829–1833. 2005. View Article : Google Scholar : PubMed/NCBI
12	Kuro-o M: Klotho. Pflugers Arch. 459:333–343. 2010. View Article : Google Scholar
13	Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S and Yamashita T: Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 444:770–774. 2006. View Article : Google Scholar : PubMed/NCBI
14	Kuro-o M: Klotho and aging. Biochim Biophys Acta. 1790:1049–1058. 2009. View Article : Google Scholar : PubMed/NCBI
15	Yamamoto M, Clark JD, Pastor JV, Gurnani P, Nandi A, Kurosu H, Miyoshi M, Ogawa Y, Castrillon DH, Rosenblatt KP, et al: Regulation of oxidative stress by the anti-aging hormone klotho. J Biol Chem. 280:38029–38034. 2005. View Article : Google Scholar : PubMed/NCBI
16	Ito S, Kinoshita S, Shiraishi N, Nakagawa S, Sekine S, Fujimori T and Nabeshima YI: Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein. Mech Dev. 98:115–119. 2000. View Article : Google Scholar : PubMed/NCBI
17	Hu MC and Moe OW: Klotho as a potential biomarker and therapy for acute kidney injury. Nat Rev Nephrol. 8:423–429. 2012. View Article : Google Scholar : PubMed/NCBI
18	Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA and Kuro-o M: Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem. 282:26687–26695. 2007. View Article : Google Scholar : PubMed/NCBI
19	Goetz R, Beenken A, Ibrahimi OA, Kalinina J, Olsen SK, Eliseenkova AV, Xu C, Neubert TA, Zhang F, Linhardt RJ, et al: Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol. 27:3417–3428. 2007. View Article : Google Scholar : PubMed/NCBI
20	Wolf I, Levanon-Cohen S, Bose S, Ligumsky H, Sredni B, Kanety H, Kuro-o M, Karlan B, Kaufman B, Koeffler HP, et al: Klotho: A tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene. 27:7094–7105. 2008. View Article : Google Scholar : PubMed/NCBI
21	Xie B, Zhou J, Yuan L, Ren F, Liu DC, Li Q and Shu G: Epigenetic silencing of Klotho expression correlates with poor prognosis of human hepatocellular carcinoma. Hum Pathol. 44:795–801. 2013. View Article : Google Scholar
22	Chen B, Wang X, Zhao W and Wu J: Klotho inhibits growth and promotes apoptosis in human lung cancer cell line A549. J Exp Clin Cancer Res. 29:992010. View Article : Google Scholar : PubMed/NCBI
23	Zhu Y, Xu L, Zhang J, Xu W, Liu Y, Yin H, Lv T, An H, Liu L, He H, et al: Klotho suppresses tumor progression via inhibiting PI3K/Akt/GSK3β/Snail signaling in renal cell carcinoma. Cancer Sci. 104:663–671. 2013. View Article : Google Scholar : PubMed/NCBI
24	Doi S, Zou Y, Togao O, Pastor JV, John GB, Wang L, Shiizaki K, Gotschall R, Schiavi S, Yorioka N, et al: Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem. 286:8655–8665. 2011. View Article : Google Scholar : PubMed/NCBI
25	Poh W, Wong W, Ong H, Aung MO, Lim SG, Chua BT and Ho HK: Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma. Mol Cancer. 11:142012. View Article : Google Scholar : PubMed/NCBI
26	Ye X, Guo Y, Zhang Q, Chen W, Hua X, Liu W, Yang Y and Chen G: βKlotho suppresses tumor growth in hepatocellular carcinoma by regulating Akt/GSK-3β/cyclin D1 signaling pathway. PLoS One. 8:e556152013. View Article : Google Scholar
27	Feng S, Dakhova O, Creighton CJ and Ittmann M: Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res. 73:2551–2562. 2013. View Article : Google Scholar : PubMed/NCBI
28	Kim HS, Kim M, Jeong CW, Kwak C, Kim HH and Ku JH: Presence of lymphovascular invasion in urothelial bladder cancer specimens after transurethral resections correlates with risk of upstaging and survival: A systematic review and meta-analysis. Urol Oncol. 32:1191–1199. 2014. View Article : Google Scholar : PubMed/NCBI
29	Cho KS, Seo HK, Joung JY, Park WS, Ro JY, Han KS, Chung J and Lee KH: Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J Urol. 182:2625–2630. 2009. View Article : Google Scholar : PubMed/NCBI